Madrigal Pharmaceuticals stock trades at 384.25 euros Friday
Published on 10/30/2026 at 18:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming Results And Business Focus
- Madrigal plans to release its third-quarter 2026 results on November 3.
- The biopharmaceutical company is focused on therapies for metabolic dysfunction-associated steatohepatitis.
Madrigal Pharmaceuticals stock traded at 384.25 euros on Lang & Schwarz at 6:36 p.m. CET on Friday, October 30.
The company plans to release its third-quarter 2026 financial results on November 3, according to the Madrigal investor-relations website. The earnings call is scheduled for 8:00 a.m. Eastern time that day.
MASH Remains The Strategic Focus
Madrigal is a biopharmaceutical company developing therapies for metabolic dysfunction-associated steatohepatitis, or MASH. Its first therapy received accelerated approval from the U.S. Food and Drug Administration for adults with noncirrhotic MASH and moderate to advanced liver fibrosis.
Investors can follow the real-time quote of Madrigal Pharmaceuticals stock as the company approaches its results release. The upcoming report may provide the next scheduled update on operating performance and the development of its MASH business.
Madrigal Pharmaceuticals at a glance
- Company: Madrigal Pharmaceuticals, Inc.
- ISIN: US5588681057
- Ticker: MDGL
- Listing: NASDAQ
- Quote: 384.25 euros on Lang & Schwarz at 6:36 p.m. CET on October 30, 2026
Broader U.S. market coverage is available through the S&P 500.
